This is a small, pre-announced sale by a non-executive officer and is unlikely to impact the stock price. Traders should monitor for actual execution of the sale and any pattern of additional insider selling, but this filing alone does not signal material concern.
TYRA drugs
TYRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 14 $35.27entry
- T+1 · 7mo ago −0.85%α −1.63% · $34.97
- T+5 · 7mo ago +4.03%α +2.63% · $36.69
- T+20 · 6mo ago −3.57%α −9.87% · $34.01
- T+60 · 4mo ago −6.41%α −14.93% · $33.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Daniel Bensen, an officer of Tyra Biosciences, filed a Form 144 to notify intent to sell up to 8,000 shares of common stock, valued at approximately $285,000, in two planned transactions on February 12 and March 12, 2026. This represents a routine, small-scale disposal of founder shares.
Key Facts
- Reporting person: Daniel Bensen, Officer
- Shares intended for sale: 8,000 shares (split across two planned sales)
- Total value of shares: $285,000 (average price ~$35.63/share)
- Shares are founder shares originally issued on August 28, 2018
- Planned sale dates: February 12, 2026, and March 12, 2026
- Broker: Merrill Lynch
Financial Impact
Approximately $285,000 in total value, representing a minor, pre-planned divestment.
Risk Factors
- Perception of insider selling could create minor downward pressure if market sentiment is fragile
- Failure to execute the sale as planned could signal changing sentiment, though not required
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-024915 |
| Document: 0001628280-26-024915-index.html | 0001628280-26-024915 |
| Document: 0001628280-26-024915.txt | 0001628280-26-024915 |
Track record
13 reports on TYRA
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers